

# CITATION REPORT

List of articles citing

Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta

DOI: 10.1124/jpet.105.092544

Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 654-61.

**Source:** <https://exaly.com/paper-pdf/39672346/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. <i>BJU International</i> , <b>2006</b> , 98, 1259-63	5.6	136
62	Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. <i>European Journal of Pharmacology</i> , <b>2006</b> , 541, 184-90	5.3	26
61	Against the motion. <i>European Urology</i> , <b>2006</b> , 49, 751-752	10.2	
60	Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. <i>Brain Research</i> , <b>2006</b> , 1118, 192-8	3.7	114
59	Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. <i>Circulation</i> , <b>2007</b> , 116, 233-5	16.7	5
58	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <i>Core Evidence</i> , <b>2007</b> ,	4.9	
57	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. <i>British Journal of Pharmacology</i> , <b>2007</b> , 150, 567-76	8.6	42
56	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , <b>2007</b> , 51, 75-88; discussion 89	10.2	73
55	Vardenafil increases coronary flow response to hypercapnic acidosis in isolated guinea pig heart. <i>Basic Research in Cardiology</i> , <b>2007</b> , 102, 115-22	11.8	4
54	Mechanisms of the relaxant effect of vardenafil in rat penile arteries. <i>European Journal of Pharmacology</i> , <b>2008</b> , 586, 283-7	5.3	18
53	Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. <i>Urology</i> , <b>2008</b> , 72, 711-5	1.6	13
52	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <i>Circulation: Heart Failure</i> , <b>2008</b> , 1, 272-80	7.6	43
51	Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 501-7	1.9	19
50	Treatment of pediatric pulmonary hypertension. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 509-24	4.4	17
49	Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. <i>International Journal of Impotence Research</i> , <b>2009</b> , 21, 221-7	2.3	80
48	Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. <i>Hypertension</i> , <b>2009</b> , 53, 1091-7	8.5	19
47	TNF-alpha knockout mice have increased corpora cavernosa relaxation. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 115-25	1.1	34

46	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 658-74.1		38
45	Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2009</b> , 36, 358-66	3	5
44	The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. <i>British Journal of Pharmacology</i> , <b>2009</b> , 156, 909-19	8.6	46
43	Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. <i>Urology</i> , <b>2009</b> , 74, 216-21	1.6	10
42	Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. <i>Journal of Pharmacological Sciences</i> , <b>2009</b> , 111, 235-43	3.7	40
41	Phosphodiesterase type 5 inhibitors: unmet needs. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3476-85	3.3	25
40	Sildenafil in the management of the failing Fontan circulation. <i>Cardiology in the Young</i> , <b>2010</b> , 20, 522-5	1	52
39	Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia. <i>Pregnancy Hypertension</i> , <b>2011</b> , 1, 231-7	2.6	5
38	Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes. <b>2011</b> ,		
37	High-fat diet associated with obesity induces impairment of mouse corpus cavernosum responses. <i>BJU International</i> , <b>2011</b> , 107, 1628-34	5.6	27
36	The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. <i>Urologia Internationalis</i> , <b>2011</b> , 86, 197-203	1.9	30
35	Beneficial effect of vardenafil on aortic stiffness and wave reflections. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 1215-21	2.9	8
34	Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. <i>Scientific World Journal, The</i> , <b>2012</b> , 2012, 718279	2.2	11
33	Vardenafil ameliorates calcium mobilization in pulmonary artery smooth muscle cells from hypoxic pulmonary hypertensive mice. <i>Archives of Medical Research</i> , <b>2012</b> , 43, 265-73	6.6	4
32	Endothelial dysfunction enhances the pulmonary and systemic vasodilator effects of phosphodiesterase-5 inhibition in awake swine at rest and during treadmill exercise. <i>Experimental Biology and Medicine</i> , <b>2012</b> , 237, 201-10	3.7	9
31	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. <i>Pediatric Health, Medicine and Therapeutics</i> , <b>2012</b> , 59	2.5	
30	Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. <i>European Journal of Pharmacology</i> , <b>2012</b> , 674, 345-51	5.3	17
29	Fatal hemorrhagic infarction of posterior fossa meningioma during cardiopulmonary bypass. <i>Annals of Thoracic Surgery</i> , <b>2012</b> , 93, 653-6	2.7	1

28	Type B aortic dissection after the use of tadalafil. <i>Annals of Thoracic Surgery</i> , <b>2012</b> , 93, 651-3	2.7	4
27	ULTIMATE-SHF trial (Udenafil Therapy to Improve symptoMATology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. <i>Trials</i> , <b>2013</b> , 14, 188	2.8	7
26	The lignan (-)-cubebin inhibits vascular contraction and induces relaxation via nitric oxide activation in isolated rat aorta. <i>Phytotherapy Research</i> , <b>2013</b> , 27, 1784-9	6.7	9
25	Pharmacotherapy of Pulmonary Hypertension. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> ,	3.2	2
24	Pediatric pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , <b>2013</b> , 15, 606-13	4.7	4
23	Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil. <i>European Journal of Pharmacology</i> , <b>2013</b> , 710, 110-9	5.3	12
22	Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 960-71	1.1	35
21	The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. <i>Cardiovascular Research</i> , <b>2013</b> , 99, 395-403	9.9	45
20	An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in rats. <i>Indian Journal of Pharmacology</i> , <b>2014</b> , 46, 185-90	2.5	4
19	Celecoxib modulates nitric oxide and reactive oxygen species in kidney ischemia/reperfusion injury and rat aorta model of hypoxia/reoxygenation. <i>Vascular Pharmacology</i> , <b>2014</b> , 62, 24-31	5.9	26
18	Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries. <i>Journal of Pharmacy and Pharmacology</i> , <b>2015</b> , 67, 87-95	4.8	14
17	PDE4 and PDE5 regulate cyclic nucleotide contents and relaxing effects on carbachol-induced contraction in the bovine abomasum. <i>Journal of Veterinary Medical Science</i> , <b>2015</b> , 77, 15-9	1.1	3
16	Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. <i>Journal of Smooth Muscle Research</i> , <b>2015</b> , 51, 22-36	0.4	5
15	Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1165-73	2.8	2
14	Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. <i>Vascular Pharmacology</i> , <b>2015</b> , 73, 71-7	5.9	10
13	Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 3455-3481	4.3	25
12	Discovery of furyl/thienyl Ecaboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 158, 767-780	6.8	7
11	The hypertensive effect of sorafenib is abolished by sildenafil. <i>Cardio-Oncology</i> , <b>2020</b> , 6, 7	2.8	2

10	Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia. <i>International Journal of Neuroscience</i> , <b>2020</b> , 1-13	2	6
9	Hydrogen Sulfide in Pharmacotherapy, Beyond the Hydrogen Sulfide-Donors. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	39
8	Relaxation effects of toward tracheal smooth muscle via action mechanism on histamine-1 receptor and phosphodiesterase-5 enzyme. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , <b>2021</b> , 12, 67-72	2.1	0
7	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , <b>2015</b> , 85, 215-24	0.2	6
6	cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. <i>PLoS ONE</i> , <b>2012</b> , 7, e53319	3.7	97
5	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129327	3.7	24
4	Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia. <i>Current Neurovascular Research</i> , <b>2019</b> , 16, 27-39	1.8	5
3	Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , <b>2016</b> , 7, 177-181	0.2	2
2	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> , 218, 229-55	3.2	2
1	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <i>Core Evidence</i> , <b>2008</b> , 2, 225-31	4.9	2